Ropes & Gray represented Sanofi in its role as co-lead investor in Atalanta Therapeutics’ $97 million Series B financing. Atalanta is a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases.
The financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from other new investors RiverVest Venture Partners, funds managed by abrdn Inc, Novartis Venture Fund, Pictet Alternative Advisors, Mirae Asset Financial Group, and GHR Foundation alongside existing investor F-Prime Capital.
The Ropes & Gray team included venture capital and emerging companies associates Daniel Freshman and Derek Mubiru, venture capital and emerging companies partner Rajarshi Banerjee, and litigation & enforcement partner Brendan Hanifin.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.